Prevention of ovarian hyperstimulation syndrome in GnRH agonist IVF cycles in moderate risk patients: Randomized study comparing hydroxyethyl starch versus cabergoline and hydroxyethyl starch

European Journal of Obstetrics and Gynecology and Reproductive Biology

Volumn 170, Issue 2, 2013, Pages 439-443

  Matorras, Roberto ^a,b   Andrés, Maider ^a   Mendoza, Rosario ^a   Prieto, Begoña ^a,b   Pijoan, Jose Ignacio ^a,b   Expósito, Antonia ^a  

^a HOSPITAL DE CRUCES   (Spain)

^b UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

Author keywords

Cabergoline; Hydroxyethyl starch; IVF; OHSS; Prevention

Indexed keywords

CABERGOLINE; CHORIONIC GONADOTROPIN; ESTRADIOL; GONADORELIN AGONIST; HETASTARCH;

ADULT; ANALGESIA; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; ESTRADIOL BLOOD LEVEL; FEMALE; FERTILIZATION IN VITRO; FOLLICULAR ASPIRATION; FOLLOW UP; HOSPITALIZATION; HUMAN; INFUSION; MAJOR CLINICAL STUDY; OVARY HYPERSTIMULATION; PARACENTESIS; PREGNANCY RATE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL;

CABERGOLINE; HYDROXYETHYL STARCH; IVF; OHSS; PREVENTION;

ADULT; DOPAMINE AGONISTS; DRUG THERAPY, COMBINATION; ERGOLINES; FEMALE; FERTILIZATION IN VITRO; GONADOTROPIN-RELEASING HORMONE; HUMANS; HYDROXYETHYL STARCH DERIVATIVES; OVARIAN HYPERSTIMULATION SYNDROME; OVULATION INDUCTION; PLASMA SUBSTITUTES; PREGNANCY; PREGNANCY RATE; PROSPECTIVE STUDIES; SECONDARY PREVENTION; TRIPTORELIN PAMOATE;

EID: 84885178889     PISSN: 03012115     EISSN: 18727654     Source Type: Journal    
DOI: 10.1016/j.ejogrb.2013.07.010     Document Type: Article

References (39)

1. A. Delvinge Request for information on unreported cases of severe ovarian hyperstimulations syndrome (OHSS) Hum Reprod 20 2005 2033
2. C.O. Nastri, R.A. Ferriani, I.A. Rocha, and W.P. Martins Ovarian hyperstimulation syndrome: pathophysiology and prevention J Assist Reprod Genet 27 2010 121 128
3. P. Humaidan, S. Kol, E. Papanikolaou, and On behalf of the 'The Copenhagen GnRH Agonist Triggering Workshop Group' GnRH agonist for triggering of final oocyte maturation: time for a change of practice Hum Reprod Update 17 2011 510 524
4. R.H. Asch, G. Ivey, M. Goldsman, J.L. Frederick, S.C. Stone, and J.P. Balmaceda The use of intravenous albumin in patients at high risk of severe ovarian hyperstimulation syndrome Hum Reprod 8 1993 1015 1020
5. E. Shalev, Y. Giladi, M. Matilsky, and M. Ben-Ami Decreased incidence of ovarian hyperstimulation syndrome in high risk in-vitro fertilization patients receiving intravenous albumin: a prospective study Hum Reprod 10 1995 1373 1376
6. A.Z. Isik, O. Gokmen, H.B. Zeyneloglu, S. Kara, G. Keles, and B. Gulekli Intravenous albumin prevents moderate-severe ovarian hyperstimulation in in-vitro fertilization patients: a prospective, randomized and controlled study Eur J Obstet Gynecol Reprod Biol 70 1996 179 183
7. C.D. Chen, H.F. Chen, H.F. Lu, S.U. Chen, H.N. Ho, and Y.S. Yang Value of serum and follicular fluid cytokine profile in the prediction of moderate to severe ovarian hyperstimulation syndrome Hum Reprod 15 2000 1037 1042
8. S. Kissler, B. Neidhardt, E. Siebzehnrübl, H. Schmitt, K. Tschaikowsky, and L. Wildt The detrimental role of colloidal volume substitutes in severe ovarian hyperstimulation syndrome: a case report Eur J Obstet Gynecol Reprod Biol 99 2001 131 134
9. M.A. Youssef, H.G. Al-Inany, J.L. Evers, and M. Aboulghar Intra-venous fluids for the prevention of severe ovarian hyperstimulation syndrome CDS Rev 16 2011 CD001302
10. A. Delvigne, and S. Rozenberg Epidemiology and prevention of ovarian hyperstimulation syndrome (OHSS): a review Hum Reprod Update 8 2002 559 577
11. M.A. Youssef, M. van Wely, M.A. Hassan, H.G. Al-Inany, M. Mochtar, and S. Khattab Can dopamine agonists reduce the incidence and severity of OHSS in IVF/ICSI treatment cycles? A systematic review and meta-analysis Hum Reprod Update 16 2010 459 466
12. H. Tang, T. Hunter, Y. Hu, S.D. Zhai, X. Sheng, and R.J. Hart Cabergoline for preventing ovarian hyperstimulation syndrome CDS Rev 2 2012 CD008605
13. C. Alvarez, I. Alonso-Muriel, and G. García Implantation is apparently unaffected by the dopamine agonist Cabergoline when administered to prevent ovarian hyperstimulation syndrome in women undergoing assisted reproduction treatment: a pilot study Hum Reprod 12 2007 3210 3214
14. C. Alvarez, L. Martí-Bonmatí, E. Novella-Maestre, R. Sanz, R. Gómez, and M. Fernández-Sánchez Dopamine agonist cabergoline reduces hemoconcentration and ascites in hyperstimulated women undergoing assisted reproduction J Clin Endocrinol Metab 92 2007 2931 2937
15. R. Gomez, C. Simon, J. Remohi, and A. Pellicer Vascular endothelial growth factor receptor-2 activation induces vascular permeability in hyperstimulated rats and this effect is prevented by receptor blockade Endocrinology 143 2002 4339 4348
16. R. Matorras, E. Urquijo, R. Mendoza, B. Corcóstegui, A. Expósito, and F.J. Rodríguez-Escudero Ultrasound-guided embryo transfer improves pregnancy rates and increases the frequency of easy transfers Hum Reprod 17 2002 1762 1766
17. R. Matorras, R. Mendoza, A. Expósito, and F.J. Rodriguez-Escudero Influence of the time interval between embryo catheter loading and discharging on the success of IVF Hum Reprod 19 2004 2027 2030
18. R. Matorras, B. Prieto, A. Exposito, R. Mendoza, L. Crisol, and P. Herranz Mid-follicular LH supplementation in women aged 35-39 years undergoing ICSI cycles: a randomized controlled study Reprod Biomed Online 19 2009 879 887
19. K.F. Schulz, D.G. Altman, D. Moher, and for the CONSORT Group CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials BMJ 340 2010 c332
20. A. Golan, R. Ron-El, A. Herman, Y. Soffer, Z. Weinraub, and E. Caspi Ovarian hyperstimulation syndrome: an update review Obstet Gynecol Surv 44 1989 430 440
21. C.A. Lyons, C.A. Wheeler, G.N. Frishman, R.J. Hackett, B.D. Seifer, and R.V. Haning Jr. Early and late presentation of the ovarian hyperstimulation syndrome: two distinct entities with different risk factors Hum Reprod 9 1994 792 799
22. A. Delvigne, A. Demoulin, J. Smitz, J. Donnez, P. Koninckx, and M. Dhont The ovarian hyperstimulation syndrome in in-vitro fertilization: a Belgian multicentric study. I. Clinical and biological features Hum Reprod 8 1993 1353 1360
23. A. Delvigne, M. Dubois, B. Battheu, S. Bassil, C. Meuleman, and P. De Sutter The ovarian hyperstimulation syndrome in in-vitro fertilization: a Belgian multicentric study. II. Multiple discriminant analysis for risk prediction Hum Reprod 9 1993 1361 1366
24. N.F. Vlahos, and O. Gregoriou Prevention and management of ovarian hyperstimulation syndrome Ann N Y Acad Sci 1092 2006 247 264
25. R. Babayof, E.J. Margalioth, M. Huleihel, A. Amash, E. Zylber-Haran, and M. Gal Serum inhibin A, VEGF and TNFalpha levels after triggering oocyte maturation with GnRH agonist compared with HCG in women with polycystic ovaries undergoing IVF treatment: a prospective randomized trial Hum Reprod 21 2006 1260 1265
26. L. Engmann, A. DiLuigi, D. Schmidt, J. Nulsen, D. Maier, and C. Benadiva The use of gonadotrophin-releasing hormone (9GnRH) agonist to induce oocyte maturation after cotreatment with GnRH antagonist in high risk patients undergoing in vitro fertilization syndrome: a prospective randomized controlled study Fertil Steril 89 2008 84 91
27. D. Navot, A. Relou, A. Birkenfeld, R. Rabinowitz, A. Brzezinski, and E. Margalioth Risk factors and prognostic variables in the ovarian hyperstimulation syndrome Am J Obstet Gynecol 159 1988 210 215
28. R.S. Morris, R.J. Paulson, M.V. Sauer, and R.A. Lobo Predictive value of serum oestradiol concentrations and oocyte number in severe ovarian hyperstimulation syndrome Hum Reprod 4 1995 811 814
29. R.S. Mathur, A.V. Akande, S.D. Keay, L.P. Hunt, and J.M. Jenkins Distinction between early and late ovarian hyperstimulation syndrome Fertil Steril 73 2000 901 907
30. M.A. Graf, R. Fischer, O.G. Naether, V. Baukloh, J. Tafel, and M. Nückel Reduced incidence of ovarian hyperstimulation syndrome by prophylactic infusion of hydroxyaethyl starch solution in an in-vitro fertilization programme Hum Reprod 12 1997 2599 2602
31. K.M. Seow, Y.H. Lin, and C.H. Bai Clinical outcome according to timing of cabergoline initiation for prevention of OHSS: a randomized controlled trial Reprod Biomed Online 26 2013 562 568
32. O. Gokmen, M. Ugur, M. Ekin, G. Keles, C. Turan, and H. Oral Intravenous albumin versus hydroxyethyl starch for the prevention of ovarian hyperstimulation in an in-vitro fertilization programme: a prospective randomized placebo controlled study Eur J Obstet Gynecol Reprod Biol 96 2001 187 192
33. E. Konig, S. Bussen, M. Sutterlin, and T. Steck Prophylactic intravenous hydroxyethyl starch solution prevents moderate-severe ovarian hyperstimulation in in-vitro fertilization patients: a prospective, randomized, double-blind and placebo-controlled study Hum Reprod 13 1998 2421 2424
34. C. Carizza, V. Abdelmassih, and S. Abdelmassih Cabergoline reduces the early onset of ovarian hyperstimulation syndrome: a prospective randomized study Reprod Biomed Online 17 2008 751 755
35. A. Shaltout, A. Shohayeb, M. Eid, and S. Abbas Role of cabergoline in preventing ovarian hyperstimlation syndrome in high risk intracytoplasmic sperm injection (ICSI) patients and effect on outcome Abstracts of the 25th annual meeting of ESHRE 2009 Amsterdam, The Netherlands 2009
36. A.M.R. Salah Edeen, and Y.M. Alhelou Can cabergoline prevent ovarian hyperstimulation syndrome in PCO patients undergoing gonadotropin stimulation? Comparative study with prednisolone Abstracts of the 25th annual meeting of ESHRE 2009 Amsterdam, The Netherlands 2009
37. R. Zanettini, A. Antonini, G. Gatto, R. Gentile, S. Tesei, and G. Pezzoli Valvular heart disease and the use of dopamine agonists for Parkinson's disease N Engl J Med 356 2007 39 46
38. A. Shaltout, A. Shohyab, and M.A. Youssef Can dopamine agonist at a low dose reduce ovarian hyperstimulation syndrome in women at risk undergoing ICSI treatment cycles: a randomized controlled study Eur J Obstet Gynecol Reprod Biol 165 2012 254 258
39. R. Schade, F. Andersohn, S. Suissa, W. Haverkamp, and E. Garbe Dopamine agonists and the risk of cardiac-valve regurgitation N Engl J Med 356 2007 29 38